Modified vaccinia Ankara expressing HIVA antigen stimulates HIV-1-specific CD8 T cells in ELISpot assays of HIV-1 exposed infants[star]
Date
2005Author
Slyker, Jennifer A
Lohman, Barbara L
Mbori-Ngacha, DA
Reilly, Marie
Wee, Edmund G T
Dong, Tao
McMichael, Andrew J
Rowland-Jones, Sarah L
Hanke, Tomas
John-Stewart, Grace
Type
ArticleLanguage
enMetadata
Show full item recordAbstract
Recombinant modified vaccinia virus Ankara expressing HIV-1 antigens (MVA.HIVA) was used in ELISpot assays to monitor HIV-1-specific T cell responses in infants. Responses to MVA.HIVA and HIV-1 peptides were examined in 13 infected and 81 exposed uninfected infants in Nairobi, Kenya. Responses to MVA.HIVA (38%) and peptide stimulation (38%) were similar in frequency (p = 1.0) and magnitude (mean 176 versus 385 HIVSFU/106, p = 0.96) in HIV-1 infected infants. In exposed uninfected infants, MVA.HIVA detected more positive responses and higher magnitude responses as compared to peptide. MVA.HIVA ELISpot is a sensitive method for quantification of HIV-1-specific CD8+ T cell responses in HIV-1 exposed infants. These results demonstrate the relevance of HIV-1 clade A consensus-derived immunogen HIVA for the viruses currently circulating in Nairobi.
URI
http://www.ncbi.nlm.nih.gov/pubmed/16043269http://erepository.uonbi.ac.ke:8080/xmlui/handle/123456789/16307
Citation
Vaccine. 2005 September 7; 23(38): 4711–4719.Publisher
Department of Medical Microbiology Department of Paediatrics
Description
Full text
Collections
- Faculty of Health Sciences (FHS) [10377]